Trials / No Longer Available
No Longer AvailableNCT01646593
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
An Open-label Expanded Access Program of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy. Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib (BAY73-4506) | 160 mg BAY73-4506, 3 weeks on drug, 1 week off |
Timeline
- First posted
- 2012-07-20
- Last updated
- 2014-12-15
Source: ClinicalTrials.gov record NCT01646593. Inclusion in this directory is not an endorsement.